Medication adherence: Importance, issues and policy: A policy statement from the American Heart Association.

Autor: Piña IL; Wayne State University, Central Michigan University, Detroit, MI, United States of America. Electronic address: ileana.pina@fda.hhs.gov., Di Palo KE; Montefiore Medical Center, Bronx, NY, United States of America., Brown MT; Rush University Medical Center, Chicago, IL, United States of America., Choudhry NK; Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America., Cvengros J; Rush University Medical Center, Chicago, IL, United States of America., Whalen D; Boston University School of Medicine, Boston, MA, United States of America., Whitsel LP; American Heart Association, Washington, DC, United States of America., Johnson J; American Heart Association, Washington, DC, United States of America.
Jazyk: angličtina
Zdroj: Progress in cardiovascular diseases [Prog Cardiovasc Dis] 2021 Jan-Feb; Vol. 64, pp. 111-120. Date of Electronic Publication: 2020 Aug 12.
DOI: 10.1016/j.pcad.2020.08.003
Abstrakt: Medications do not work in patients who do not take them. This true statement highlights the importance of medication adherence. Providers are often frustrated by the lack of consistent medication adherence in the patients they care for. Today with the time constraints that providers face, it becomes difficult to discover the extent of non-adherence. There are certainly many challenges in medication adherence not only at the patient-provider level but also within a healthy system and finally in insurers and payment systems. In a cross-sectional survey of unintentional nonadherence in over 24,000 adults with chronic illness, including hypertension, diabetes and hyperlipidemia, 62% forgot to take medications and 37% had run out of their medications within a year. These sobering data necessitate immediate policy and systems solutions to support patients in adherence. Medication adherence for cardiovascular diseases (CVD) has the potential to change outcomes, such as blood pressure control and subsequent events. The American Heart Association (AHA)/American Stroke Association (ASA) has a goal of improving medication adherence in CVD and stroke prevention and treatment. This paper will explore medication adherence with all its inherent issues and suggest policy and structural changes that must happen in order to transform medication adherence levels in the U.S. and achieve the AHA/ASA's health impact goals.
Competing Interests: Declaration of competing interest Dr. Piña is a member of the Advisory Board for Relypsa and Astra Zeneca. Dr. Choudhry reports research support from Astra Zeneca and Sanofi. Consultant to RxAnte. None of the other authors have reported any conflicts.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: